“Hopefully Novoheart can reinvigorate the whole drug development industry , and have a major impact on patient health ”
Kevin Costa , CSO at Novoheart
the denominator , that ’ s got to be a move forward ,” says Costa . “ You ’ re still going to be putting in a lot of money into this development , but if you can get it to pay off more and generate more effective drugs , costs will go down … and hopefully that ’ ll also restore consumer confidence in the industry .
“ You know , these examples like Vioxx and things like that happening in the market , it makes people rightly concerned that the process is a broken process ,” Costa emphasises . “ I think that is true , and I think Novoheart is a novel way to fix that process and hopefully , if the cost can go down , success rates will go up and we ’ ll start seeing more drugs . The pipeline has been kind of drying out , because there ’ s not enough companies that have the resources to invest in this process .
“ Hopefully Novoheart can reinvigorate the whole drug development industry , and have a major impact on patient health .”
47 www . healthcareglobal . com